Payment overview · 2025
General Payments
$1,039.51
9 reported records · 7 companies
Healthcare provider profile · identity verified
Soledad O Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BUENA PARK, CA · NPI 1063609097
Verified facts
What the public records show
CMS Open Payments records show Soledad O Lee, MD received $1,039.51 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $293.70 | 28.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.19 | 21.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 12.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $125.00 | 12.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 12.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $111.99 | 10.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $30.63 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,039.51 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $228.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $147.32 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $146.38 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $111.99 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $30.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 99 |
| Lovastatin | Lovastatin | 469 | 74 |
| Losartan Potassium | Losartan Potassium | 457 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 451 | 101 |
| Famotidine | Famotidine | 330 | 60 |
| Metformin Hcl | Metformin Hcl | 322 | 77 |
| Omeprazole | Omeprazole | 265 | 45 |
| Furosemide | Furosemide | 260 | 58 |
| Xarelto | Rivaroxaban | 225 | 23 |
| Dexamethasone | Dexamethasone | 198 | 121 |
| Potassium Chloride | Potassium Chloride | 191 | 45 |
| Azithromycin | Azithromycin | 175 | 111 |
| Gabapentin | Gabapentin | 149 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 30 |
| Montelukast Sodium | Montelukast Sodium | 143 | 35 |
| Carvedilol | Carvedilol | 140 | 29 |
| Lisinopril | Lisinopril | 138 | 33 |
| Alendronate Sodium | Alendronate Sodium | 137 | 24 |
| Clonidine Hcl | Clonidine Hcl | 133 | 52 |
| Albuterol Sulfate | Albuterol Sulfate | 129 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 23 |
| Levetiracetam | Levetiracetam | 119 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 33 |
| Gemfibrozil | Gemfibrozil | 112 | 14 |
| Glipizide | Glipizide | 110 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 104 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 31 |
| Ceftriaxone | Ceftriaxone Sodium | 94 | 61 |
| Mupirocin | Mupirocin | 89 | 54 |
| Ibuprofen | Ibuprofen | 81 | 41 |
| Alprazolam | Alprazolam | 80 | 30 |
| Divalproex Sodium Er | Divalproex Sodium | 76 | suppressed |
| Lactulose | Lactulose | 76 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 72 | suppressed |
| Simvastatin | Simvastatin | 72 | 17 |
| Cephalexin | Cephalexin | 68 | 54 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 68 | 46 |
| Entresto | Sacubitril/Valsartan | 68 | suppressed |
| Allopurinol | Allopurinol | 64 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 15 |
| Carbamazepine | Carbamazepine | 61 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 12 |
| Meloxicam | Meloxicam | 60 | 21 |
| Eliquis | Apixaban | 57 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 11 |
| Phenobarbital | Phenobarbital | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 41 |
| Enulose | Lactulose | 51 | suppressed |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 39 |
| Atenolol | Atenolol | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Finasteride | Finasteride | 48 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Linzess | Linaclotide | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 19 |
| Latanoprost | Latanoprost | 45 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Risperidone | Risperidone | 44 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | 14 |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 12 |
| Topiramate | Topiramate | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 37 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 36 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 11 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Lacosamide | Lacosamide | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 28 | 21 |
| Lidocaine Hcl | Lidocaine Hcl | 28 | 24 |
| Meclizine Hcl | Meclizine Hcl | 28 | 16 |
| Nitroglycerin | Nitroglycerin | 28 | 13 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 14 |
| Temazepam | Temazepam | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Haloperidol | Haloperidol | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 18 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 16 | 12 |
| Nystatin | Nystatin | 16 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 15 | 15 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Isibloom | Desogestrel-Ethinyl Estradiol | 13 | suppressed |
| Lo-Zumandimine | Ethinyl Estradiol/Drospirenone | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,039.51 · 9 records | Amgen Inc. | DAYBUE, IBSRELA, JYNARQUE, KRYSTEXXA, Ozempic, REPATHA, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error